BME · ROVI.MC
Laboratorios Farmaceuticos Rovi, S.A.
€62.20+€0.65 (+1.06%)
Laboratorios Farmaceuticos Rovi, S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.26% below the high.
Loading market information…
BME · GRF.MC · EUR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:18 AM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Grifols, S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.48% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Grifols, S.A.’s forward annual dividend is €0.08 per share, paid annual. The forward yield is 0.76% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Grifols, S.A.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of €0.29. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Grifols, S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| May 12, 2025 |
| €0.14+0.74% vs estimate |
| €1.79B+1.95% vs estimate |
| Q4 2024 | Feb 26, 2025 | €0.23+3.46% vs estimate | €1.98B+1.88% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | €0.23+14.94% vs estimate | €1.79B+1.65% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€62.20+€0.65 (+1.06%)
Laboratorios Farmaceuticos Rovi, S.A.’s quoted price sits in the lower half of its reported 52-week range, 28.26% below the high.
€10.68+€0.16 (+1.52%)
Almirall, S.A.’s quoted price sits in the lower half of its reported 52-week range, 23.61% below the high.
€4.87+€0.09 (+1.88%)
Faes Farma, S.A.’s quoted price sits in the lower half of its reported 52-week range, 10.57% below the high.
€67.55-€1.70 (-2.45%)
Pharma Mar, S.A.’s quoted price sits in the lower half of its reported 52-week range, 35.79% below the high.
€53.40-€0.40 (-0.74%)
Clínica Baviera, S.A.’s quoted price sits in the upper half of its reported 52-week range, 13.87% below the high.
€12.40-€0.05 (-0.4%)
Prim, S.A.’s quoted price sits in the lower half of its reported 52-week range, 11.11% below the high.
€2.56-€0.01 (-0.39%)
Laboratorio Reig Jofre, S.A.’s quoted price sits in the lower half of its reported 52-week range, 24.71% below the high.
€2.50+€0.00 (+0.08%)
Oryzon Genomics S.A.’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
